Search results
Moderna stock is lone omen of bird flu pandemic
Reuters· 10 hours agoThe recent rise of Moderna’s stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40% since...
Moderna says new-generation COVID vaccine more effective than Spikevax in adults 18 and over
Morningstar· 5 days ago"Today's vaccine efficacy data are consistent with the previously announced immunogenicity results from the study, which showed that mRNA-1283 had higher neutralizing antibody ...
Combined mRNA COVID-flu vaccine shows promise in Moderna trial
Semafor via Yahoo News· 7 days agoThe release comes from Moderna’s ongoing Phase... Semafor Signals: Global insights on today's...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation...
Digital Journal· 5 days agomRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and olderHigher efficacy was observed in mRNA-1283 compared
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. -...
FOX 23 News Albany· 3 days agoPomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA). Such investors are advised to ...
Apple Intelligence, Musk Reacts, Equal-Weighted S&P Signal? Trading Moderna
TheStreet.com· 7 days agoThe goal on Monday was probably to convince investors that Apple is not falling way behind in the...
Analysis | End of internet subsidy leaves millions facing telehealth disconnect
Washington Post· 7 days agoToday’s edition: An advisory panel to the Food and Drug Administration endorsed an Alzheimer’s drug on Monday. When the clock struck midnight on May 31, more than 23 million ...
What is COVID KP.3 variant? Symptoms, CDC data, what to know about the newest COVID strain
USA TODAY via Yahoo News· 6 days agoAhjané covers breaking news, car recalls, crime, health, lottery and public policy stories. Email her at aforbes@gannett.com. Follow...
The First Three Months
The Atlantic· 2 days agoA reporter calling me at home on a holiday about a possible disease outbreak was concerning, but not that unusual. The press sometimes had better, or at...
Analysis | Court rejects abortion pill challenge, but what happens next?
Washington Post· 4 days agoWhat do you think is next in the fight over medication abortion?Today’s edition: Senate Republicans...